trending Market Intelligence /marketintelligence/en/news-insights/trending/roekqbynqbe0qlqyoh2ckw2 content esgSubNav
In This List

Aptose enters $20M stock purchase agreement with Aspire Capital Fund

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


Aptose enters $20M stock purchase agreement with Aspire Capital Fund

Aptose Biosciences Inc. agreed to sell up to $20 million of its common shares to Aspire Capital Fund LLC.

Aspire Capital Fund, which invests in a broad range of industries with emphasis in healthcare and technology sector, will buy the shares at Aptose's request until April 7, 2020, subject to certain conditions.

Shares sold under the purchase agreement will be limited to 19.99% of Aptose's outstanding common stock.

Mississauga, Ontario-based Aptose develops personalized cancer therapies in Canada.